Castle Biosciences, Inc. (CSTL)
Nasdaq · Healthcare · Diagnostics & Research
$36.65+3.07%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.1B
- 52-week range
- $17.72 – $44.28
- 52-week change
- +55.15%
- EPS (trailing)
- −$0.64
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $344M (+3.66%)
- Net income
- −$24.2M
- Operating margin
- −12.4%
- Diluted EPS
- −$0.83
- Free cash flow
- $28.3M
From the company’s annual report on SEC EDGAR.
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma.
Headquarters: Friendswood, United States · 1,002 employees · castlebiosciences.com